Vera Therapeutics
VERA
30.25
+0.83
+2.82%
Vera Therapeutics
US · VERA
#2739 by market cap
Listed 2021
30.25
+0.83
+2.82%
Live - 5344 symbols - heartbeat 448s ago
· 2026-10-08 04:00
Pre-market
30.25
0.00%
After-hours
30.00
-0.83%
- Market cap
- 2.18B
- P/E (TTM)i
- -5.15
- P/Bi
- 5.35
- EPSi
- -4.66
- Div yieldi
- 0.00%
- 52W posi
- 22%
Reader sentiment
Are you bullish or bearish on VERA?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 7 years
Key ratios & quality
- Enterprise valuei
- 1.54B
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 4.41M | 4.04M | 11.92M | 21.91M | 23.79M | 41.00M | 100.22M |
| Research & development | 7.29M | 45.21M | 22.48M | 68.99M | 78.23M | 126.17M | 215.26M |
| Operating profit | -11.70M | -49.25M | -34.40M | -90.90M | -102.01M | -167.17M | -315.47M |
| Pretax profit | -11.85M | -53.41M | -32.61M | -89.06M | -95.99M | -152.15M | -299.61M |
| Tax | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K |
| Net profit | -11.85M | -53.41M | -32.61M | -89.06M | -95.99M | -152.15M | -299.62M |
| Basic EPS | -3 | -13 | -2 | -3 | -2 | -3 | -5 |
| Diluted EPS | -2.91 | -13.10 | -2.43 | -3.35 | -2.25 | -2.75 | -4.66 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 15.92M | 21.95M | 27.46M | 34.90M | 39.12M | 52.41M |
| Research & development | 41.28M | 58.20M | 56.47M | 59.31M | 86.01M | 60.08M |
| Operating profit | -57.19M | -80.14M | -83.93M | -94.21M | -125.13M | -112.49M |
| Pretax profit | -51.69M | -76.53M | -80.29M | -91.10M | -121.03M | -109.47M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -51.69M | -76.53M | -80.29M | -91.10M | -121.03M | -109.47M |
| Basic EPS | -1 | -1 | -1 | -1 | -2 | -2 |
| Diluted EPS | -0.81 | -1.20 | -1.26 | -1.39 | -1.69 | -1.52 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total current assets | 3.57M | 54.26M | 82.54M | 125.70M | 172.02M | 651.22M | 728.88M |
| Cash & ST investments | 3.20M | 53.65M | 79.67M | 114.65M | 160.72M | 640.85M | 714.59M |
| Inventory | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 5.38M | 54.55M | 83.75M | 131.44M | 175.55M | 655.68M | 734.73M |
| Total current liabilities | 1.06M | 2.41M | 7.69M | 25.60M | 22.30M | 25.37M | 53.46M |
| Short-term debt | 122.00K | -- | -- | 2.65M | 2.44M | 1.48M | 549.00K |
| Long-term debt | -- | -- | 4.92M | 24.81M | 49.88M | 50.69M | 74.84M |
| Total liabilities | 41,929,000.00 | 143,902,000.00 | 14,156,000.00 | 54,527,000.00 | 73,861,000.00 | 78,526,000.00 | 130,212,000.00 |
| Total equity | -36.55M | -89.35M | 69.59M | 76.91M | 101.69M | 577.16M | 604.52M |
| Retained earnings | -38.03M | -91.45M | -124.06M | -213.11M | -309.10M | -461.25M | -760.87M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 606.08M | 571.35M | 511.31M | 728.88M | 615.80M | 527.49M |
| Cash & ST investments | 589.83M | 556.83M | 497.39M | 714.59M | 596.76M | 499.16M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 610.17M | 578.53M | 517.50M | 734.73M | 621.74M | 532.98M |
| Total current liabilities | 21.89M | 33.55M | 41.88M | 53.46M | 45.15M | 48.32M |
| Short-term debt | 1.19M | 855.00K | 473.00K | 549.00K | -- | -- |
| Long-term debt | 50.91M | 74.46M | 74.65M | 74.84M | 75.03M | 75.23M |
| Total liabilities | 75,168,000.00 | 110,251,000.00 | 118,623,000.00 | 130,212,000.00 | 122,042,000.00 | 125,226,000.00 |
| Total equity | 535.00M | 468.28M | 398.88M | 604.52M | 499.70M | 407.76M |
| Retained earnings | -512.94M | -589.48M | -669.77M | -760.87M | -881.90M | -991.37M |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -10.29M | -34.81M | -23.71M | -67.60M | -92.18M | -134.68M | -241.10M |
| Depreciation & amortization | 509.00K | 251.00K | 176.00K | -846.00K | 21.00K | 105.00K | 468.00K |
| Free cash flow | -10.41M | -34.91M | -23.71M | -67.66M | -92.24M | -135.65M | -241.73M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 51.18M | 86.13M | 115.00M | 632.52M | 300.50M |
| Ending cash balance | 3.56M | 54.00M | 79.97M | 43.75M | 45.68M | 92.65M | 354.73M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -54.41M | -54.80M | -61.91M | -69.99M | -106.50M | -100.25M |
| Depreciation & amortization | 85.00K | 119.00K | 129.00K | 135.00K | 140.00K | 132.00K |
| Free cash flow | -54.59M | -55.01M | -62.04M | -70.10M | -106.67M | -100.37M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | 300.50M | -- | -- |
| Ending cash balance | 55.09M | 49.12M | 57.77M | 354.73M | 114.35M | 48.88M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -121.58 | -107.50 | -44.83 | -50.71 |
| ROA %i | -220.29 | -178.24 | -47.16 | -82.77 | -62.54 | -36.61 | -43.10 |
| ROIC %i | -- | -- | -- | -96.74 | -75.35 | -41.28 | -48.20 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 3.36 | 22.55 | 10.73 | 4.91 | 7.71 | 25.67 | 13.64 |
| Quick ratioi | 3.01 | 22.32 | 10.36 | 4.48 | 7.23 | 25.41 | 13.43 |
| Debt / assetsi | 2.45 | -- | 5.88 | 23.80 | 30.59 | 8.33 | 10.52 |
| LT debt / equityi | -- | -- | 7.07 | 37.24 | 50.42 | 9.21 | 12.70 |
| Interest coveragei | -231.41 | -320.76 | -1,629.40 | -88.77 | -24.35 | -18.95 | -38.78 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.00 | 0.00 | 0.00 | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -39.49 | -54.83 | -73.25 | -50.71 | -71.32 | -91.75 |
| ROA %i | -34.09 | -44.74 | -56.87 | -43.10 | -59.90 | -72.32 |
| ROIC %i | -38.42 | -50.83 | -65.87 | -48.20 | -66.16 | -81.06 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 27.68 | 17.03 | 12.21 | 13.64 | 13.64 | 10.92 |
| Quick ratioi | 27.10 | 16.72 | 11.96 | 13.43 | 13.30 | 10.41 |
| Debt / assetsi | 8.93 | 13.41 | 14.92 | 10.52 | 12.37 | 14.43 |
| LT debt / equityi | 9.96 | 16.38 | 19.24 | 12.70 | 15.39 | 18.86 |
| Interest coveragei | -22.36 | -28.21 | -32.60 | -38.78 | -47.79 | -52.34 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-08 04:00:01 · For reference only, not investment advice and not tailored to your situation.